Disc Medicine (NASDAQ:IRON) PT Raised to $43.00

Disc Medicine (NASDAQ:IRONFree Report) had its price objective boosted by Raymond James from $40.00 to $43.00 in a research report sent to investors on Friday, Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also issued reports on the company. Wedbush reaffirmed an outperform rating and set a $43.00 price target (down previously from $84.00) on shares of Disc Medicine in a research note on Monday, April 1st. Stifel Nicolaus lifted their price target on Disc Medicine from $71.00 to $73.00 and gave the stock a buy rating in a research note on Monday, April 8th. BMO Capital Markets dropped their price target on Disc Medicine from $80.00 to $50.00 and set an outperform rating for the company in a research note on Tuesday, April 2nd. Morgan Stanley dropped their price target on Disc Medicine from $75.00 to $40.00 and set an equal weight rating for the company in a research note on Tuesday, April 2nd. Finally, HC Wainwright reissued a buy rating and issued a $70.00 target price on shares of Disc Medicine in a research note on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $57.71.

View Our Latest Research Report on IRON

Disc Medicine Stock Up 2.1 %

Disc Medicine stock opened at $31.01 on Friday. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The business has a 50-day simple moving average of $42.68 and a 200 day simple moving average of $53.51. The stock has a market cap of $765.33 million, a price-to-earnings ratio of -9.17 and a beta of 0.44.

Disc Medicine (NASDAQ:IRONGet Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22). On average, research analysts anticipate that Disc Medicine will post -4.44 earnings per share for the current year.

Insider Activity

In related news, Director William Richard White sold 2,560 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.24% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its holdings in Disc Medicine by 12.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company’s stock valued at $61,469,000 after purchasing an additional 145,781 shares during the period. Perceptive Advisors LLC increased its holdings in Disc Medicine by 14.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock valued at $59,091,000 after purchasing an additional 127,404 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in Disc Medicine by 19.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company’s stock valued at $45,342,000 after purchasing an additional 130,000 shares during the period. Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 782,751 shares of the company’s stock worth $48,734,000 after acquiring an additional 18,207 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of Disc Medicine by 37.5% during the 4th quarter. Franklin Resources Inc. now owns 221,424 shares of the company’s stock worth $12,789,000 after acquiring an additional 60,403 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

See Also

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.